Clik here to view.
Porphyrias: a disease grouping by cause, not symptoms
Held biennially, the Porphyrins & Porphyrias conference (P&P) is the world’s largest gathering on the porphyrias – a group of metabolic disorders causing biochemical disruptions in the pathway...
View ArticleClik here to view.
The importance of clinical relevance
Development of novel drugs is truly like no other business: one attempts to address questions that may have never been previously posed – let alone answered – in the pursuit of improving the lives and...
View ArticleClik here to view.
Clinical relevance – the value of patient experiences
Since 2006 Clinuvel has trialed SCENESSE® in a truly unique group of individuals: patients living with erythropoietic protoporphyria (EPP), a rare genetic blood disorder which causes an absolute...
View ArticleClik here to view.
EPP results and clinical relevance
A protoporphyrin IX molecule Over recent months I have written several times of the need for Clinuvel to prove clinical relevance in our trials with the use of SCENESSE® (afamelanotide) in...
View ArticleClik here to view.
MAA: a moment in Clinuvel’s EPP story
Those who have taken an interest in Clinuvel will have learned with joy that, on Monday February 6th, the company announced its first official filing for SCENESSE® (afamelanotide) with the European...
View ArticleClik here to view.
Delivering a therapy for those who need it most: EPP in Switzerland
Earlier today we announced that two health insurers in Switzerland had agreed to reimburse SCENESSE® (afamelanotide) for the rare disease erythropoietic protoporphyria (EPP). While this is an...
View ArticleClik here to view.
Inside Clinuvel: effective drug development
Take ten years, half a billion dollars and countless man hours from some of the most highly trained, intelligent individuals on the globe. You still stand a 90% chance of failure, some of which is...
View ArticleClik here to view.
Inside Clinuvel: SCENESSE® in acne?
A new article was published last week looking at a small pilot study of SCENESSE® (afamelanotide) in acne vulgaris. Before discussing this piece specifically, I think it is relevant to briefly review...
View ArticleClik here to view.
Inside Clinuvel: Vitiligo and treatment frustrations
Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its possible causes and how SCENESSE® (afamelanotide) may become a...
View ArticleClik here to view.
‘Measuring’ vitiligo: the challenges of clinical and treatment evaluation
Since our announcement last year that Clinuvel would commence a new program for SCENESSE® (afamelanotide) in nonsegmental vitiligo, the company has received vast interest in the application of the drug...
View Article
